Yeast-based therapeutic for chronic hepatitis B infection
AssigneeGlobeImmune, Inc.
InventorsDavid Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
Life of this patent
Estimating the term…
Abstract
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.
Claims27
An immunotherapeutic composition comprising:
- a) a yeast vehicle;
- and
- b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:
- i) an HBV X antigen having an amino acid sequence that is at least 90% identical to positions 1-60 of SEQ ID NO:130;
- ii) an HBV surface antigen having an amino acid sequence that is at least 90% identical to positions 63-461 of SEQ ID NO:130;
- and
- iii) an HBV core antigen having an amino acid sequence that is at least 90% identical to positions 462 to 643 of SEQ ID NO:130;
- wherein the composition elicits an HBV-specific immune response and wherein the fusion protein is expressed by the yeast vehicle.
A yeast expressing a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:
- a) an HBV X antigen having an amino acid sequence that is at least 90% identical to positions 1-60 of SEQ ID NO:130;
- b) an HBV surface antigen having an amino acid sequence that is at least 90% identical to positions 63-461 of SEQ ID NO:130;
- and
- c) an HBV core antigen having an amino acid sequence that is at least 90% identical to positions 462 to 643 of SEQ ID NO:130.
A fusion protein comprising HBV antigens, wherein the fusion protein comprises an amino acid sequence that is at least 90% identical to an amino acid sequence of SEQ ID NO:130 or SEQ ID NO:150.
Dependencies are inferred from the claim text.